ND AML group:CRc: 96%FLT3-ITD MRD < 5 X 10-5 (within 4 cycles): 65%Median RFS, OS: NR18-month RFS: 71%18-month OS: 72%R/R AML group:CRc: 27%. This evidence concerns the gene FLT3 and acute myeloid leukemia.